Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Division of Cardiovascular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Leuk Lymphoma. 2023 Feb;64(2):445-453. doi: 10.1080/10428194.2022.2140289. Epub 2022 Nov 4.
A 21-point risk score for heart failure (HF) has been developed for patients with acute myeloid leukemia (AML), stratifying patients into three groups: low, moderate, and high-risk. In this study, 193 patients with AML treated with anthracycline-based therapy were stratified using the risk score, and its prognostic utility for HF events and all-cause mortality at one year of follow-up were evaluated. HF occurred in 18% (34/193) of anthracycline-treated patients. Global longitudinal strain (GLS) was more negative among patients without HF events (-19 ± 3 -17 ± 4%). One year incidence of HF was increased in the higher risk groups: 12% of low-risk, 24% of moderate-risk, and 50% of high-risk ( < 0.001). However, a higher risk score was not associated with an increased risk of all-cause mortality. This study provides external validation of a 21-point risk score for HF events but not all-cause mortality at one year in patients with AML.
一项针对急性髓系白血病（AML）患者的心力衰竭（HF） 21 分风险评分已经开发出来，将患者分为三组：低危、中危和高危。在这项研究中，193 名接受蒽环类药物治疗的 AML 患者使用风险评分进行分层，并评估其对 HF 事件和一年随访时全因死亡率的预后价值。在接受蒽环类药物治疗的患者中，18%（34/193）发生 HF。无 HF 事件患者的整体纵向应变（GLS）更负（-19±3 vs. -17±4%）。在更高风险组中，HF 的一年发生率增加：低危组为 12%，中危组为 24%，高危组为 50%（ < 0.001）。然而，更高的风险评分与全因死亡率的增加无关。这项研究为 AML 患者 HF 事件的 21 分风险评分提供了外部验证，但对一年时的全因死亡率则没有提供。
